Edwards Lifesciences Corp 4
4 · Edwards Lifesciences Corp · Filed Oct 29, 2014
Insider Transaction Report
Form 4
Solomon Carlyn D
CVP, Critical Care & Vascular
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Acquire)
2014-10-28$85.45/sh−21,200$1,811,540→ 21,200 totalExercise: $85.45From: 2013-05-09Exp: 2019-05-08→ Common Stock (21,200 underlying) - Exercise/Conversion
Common Stock
2014-10-28$85.45/sh+21,200$1,811,540→ 91,954 total - Exercise/Conversion
Common Stock
2014-10-28$89.23/sh+39,600$3,533,508→ 70,754 total - Exercise/Conversion
Common Stock
2014-10-28$71.57/sh+11,850$848,104→ 103,804 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2014-10-28$89.23/sh−39,600$3,533,508→ 13,200 totalExercise: $89.23From: 2012-05-12Exp: 2018-05-11→ Common Stock (39,600 underlying) - Sale
Common Stock
2014-10-28$118.00/sh−72,650$8,572,751→ 31,154 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2014-10-28$71.57/sh−11,850$848,104→ 35,550 totalExercise: $71.57From: 2014-05-14Exp: 2020-05-13→ Common Stock (11,850 underlying)
Footnotes (2)
- [F1]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $117.69 to $118.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.